EDEN PRAIRIE, Minn., April 08, 2020 (GLOBE NEWSWIRE) – CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients with fluid overload, announced today that the company will house a clinician interactive online to discuss cardiopulmonary-renal management in COVID-19 patients from the real world. Dr. Daniel J. Goldstein, Professor and Vice-Chair, Department of Cardiothoracic Surgery, Montefiore Medical Center, New York, will host the online discussion on Friday April 10 at 1:00 p.m. EDT.
Clinicians will present COVID-19 case studies in large rounds and discuss:
- Complex fluid balance and overload management
- Cardiopulmonary and hemodynamic state management strategies
- Managing the continuum of acute kidney injury (AKI) through end-stage renal disease (ESRD)
- Current strategies to treat ARDS, minimize ventilation time and the role of lying positioning
- Staff and resource challenges
- Lessons learned
Moderator: Daniel J. Goldstein, MD, FACS, FACC, Montefiore Medical Center, New York City, NY
Doctors presenting patient case studies:
- Maria DeVita, MD, FACP, FASN, nephrologist, Lenox Hill Hospital, New York City, NY
- Mehdi Oloomi, MD, intensivist, Mount Sinai Hospital, New York City, NY
- Giovanni Piovesana, MD, cardio-thoracic surgeon, Phoebe Putney Hospital, Albany, GA
“As providers seek concrete evidence to improve outcomes for critically ill patients with COVID-19, it is important that we organize and accelerate access to communication from the front lines of care,” said Daniel J Goldstein, MD, FACS, FACC, of the Montefiore Medical Center. “One of the many clinical challenges we face is watching what we learn about cardiopulmonary-renal management and this group of experienced doctors can share what they see in their patients.”
“Our commitment to help treat patients during this pandemic continues to guide the decision we make,” said John Erb, CEO of CHF Solutions. “We have heard from distinguished physicians that our ultrafiltration therapy has helped in the treatment of patients with COVID-19. Our hope is that sharing these patient case studies from attending physicians will provide other providers with information that will help them provide the best care possible during this unprecedented period. “
Register to participate in this informative webinar by following this link: https://bit.ly/3b31kM5.
For those who cannot attend the webinar, an audio archive of the webcast will be available at http://ir.chf-solutions.com/ events within 48 hours of the event.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients with fluid overload with its new ultrafiltration therapy system. The company is focused on the development, manufacturing and marketing of the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., With wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq capital market since February 2012.
About the Aquadex SmartFlow system
The Aquadex SmartFlow system offers clinically proven therapy using a simple, flexible and intelligent method to remove excess fluid from patients with hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or prolonged use (more than 8 hours in patients requiring hospitalization) in adult and pediatric patients weighing 20 kg or more whose fluid overload does not respond to medical management, including diuretics. All treatments must be administered by a health professional, on an outpatient or hospital basis, on medical prescription, both of whom have received training in extracorporeal therapies.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the treatment of patients infected with COVID-19 coronavirus. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. There are many factors that could cause actual future events to differ materially from the forward-looking statements in this release, including, but not limited to, the risks associated with our ability to execute our business strategy, the possibility that we may not be able to combine sufficient funds necessary for our planned operations, our post-marketing clinical data collection activities, the benefits of our products to patients, our expectations for product development and marketing, our ability to increase acceptance of our market and physician products, potentially competitive product offerings, asset protection, our ability to integrate acquired businesses, our expectations regarding synergies and anticipated benefits of acquired businesses, and other risks and uncertainties described in our documents filed with the SEC. Forward-looking statements are only valid on the date they are made. CHF Solutions assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 MEDIA: Jessica Stebing Health+Commerce 260-336-6202